Sergio Sanchez, MD
Internal Medicine · New Brunswick, NJNPI 1962445494
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.1%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. E.r. Squibb & Sons, L.L.C. accounts for 77.9% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $11,909, more than ten times the $109 reported in 2019. Among internal medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 206 payments — averaging $68.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$11K
- AstraZeneca$871
- Novo Nordisk$565
- Amgen$506
- Boehringer Ingelheim$268
- Bayer$242
- plus $686 from 12 others
What the payments were for
- Consulting fees$7,24551%
- Speaking & faculty fees$2,30016%
- Travel & lodging$1,2008%
- Food & beverage$3,44024%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 10 | $11,055 |
| AstraZeneca | 47 | $871 |
| Novo Nordisk | 50 | $565 |
| Amgen | 34 | $506 |
| Boehringer Ingelheim | 17 | $268 |
| Bayer | 12 | $242 |
| Esperion Therapeutics, Inc. | 4 | $159 |
| Exact Sciences | 6 | $104 |
| Abbott | 5 | $99 |
| Lilly USA, LLC | 5 | $91 |
| Kowa Pharmaceuticals America, Inc. | 3 | $44 |
| Amarin Pharma, Inc. | 3 | $41 |
| Merck | 3 | $39 |
| Xeris Pharmaceuticals, Inc. | 2 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $26 |
| Dexcom, Inc. | 1 | $22 |
| Intuity Medical Inc | 1 | $18 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,191 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 48 | $58,830 |
| OzempicSemaglutide | 29 | $47,581 |
| TrulicityDulaglutide | 32 | $42,945 |
| JardianceEmpagliflozin | 43 | $41,364 |
| EliquisApixaban | 32 | $28,164 |
| RybelsusSemaglutide | 20 | $22,610 |
| Atorvastatin Calcium | 264 | $4,413 |
| Humalog Kwikpen U-100Insulin Lispro | 21 | $3,849 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $3,829 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $3,802 |
| Olmesartan Medoxomil | 66 | $3,694 |
| Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm | 14 | $3,615 |
| Rosuvastatin Calcium | 206 | $3,596 |
| Metformin Hcl ErMetformin Hcl | 255 | $3,027 |
| Omeprazole | 100 | $2,492 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $565 | $70,19249 claims |
| AstraZenecaFarxiga | $871 | $58,83048 claims |
| Lilly USA, LLCTrulicity | $91 | $42,94532 claims |
| Boehringer IngelheimJardiance | $268 | $41,36443 claims |
| PfizerEliquis | $13 | $28,16432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in New Brunswick
- Stephen MarcellaNew Brunswick$331K
- Steven PeskinNew Brunswick$99K
- James CoromilasNew Brunswick$32K
- Jeffrey CarsonNew Brunswick$31K
- David KountzNew Brunswick$23K
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Viju VijaysadanKinnelon$325K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.